585
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective

, , , , , , , , , & show all
Pages 173-181 | Published online: 18 Jan 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Ali A Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto & Manfredi Rizzo. (2015) Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy 15:10, pages 1391-1397.
Read now
Manfredi Rizzo, Noor Al-Busaidi & Ali A Rizvi. (2015) Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Expert Opinion on Pharmacotherapy 16:3, pages 281-284.
Read now
Manfredi Rizzo, Giuseppe Montalto & Khalid Al-Rasadi. (2014) Treatment options for managing atherogenic dyslipidemia and fatty liver disease. Expert Opinion on Pharmacotherapy 15:8, pages 1065-1068.
Read now
Dragana Nikolic, Peter P Toth, Alessandra Ferlita, Vittoria Di Bartolo, Giuseppe Montalto, Maciej Banach & Manfredi Rizzo. (2014) Novel anti-obesity drugs and plasma lipids. Clinical Lipidology 9:2, pages 179-187.
Read now
Manfredi Rizzo, Angelo Avogaro, Giuseppe Montalto & Ali A Rizvi. (2013) Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets 17:7, pages 739-742.
Read now
Pablo Perez- Martinez, Manfredi Rizzo, Giuseppe Montalto & Jose Lopez- JMiranda. (2013) Postprandial metabolism: from research to clinical practice. Clinical Lipidology 8:4, pages 395-398.
Read now

Articles from other publishers (13)

Jelena Vekic, Anca Pantea Stoian & Manfredi Rizzo. (2023) Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients. Journal of Diabetes and its Complications 37:3, pages 108412.
Crossref
Junpei Sanada, Atsushi Obata, Yoshiyuki Obata, Yoshiro Fushimi, Masashi Shimoda, Kenji Kohara, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku & Hideaki Kaneto. (2021) Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better. Scientific Reports 11:1.
Crossref
Louise Vedtofte, Emilie Bahne, Signe Foghsgaard, Jonatan I. Bagger, Camilla Andreasen, Charlotte Strandberg, Peter M. Gørtz, Jens J. Holst, Henning Grønbæk, Jens A. Svare, Tine D. Clausen, Elisabeth R. Mathiesen, Peter Damm, Lise L. Gluud, Filip K. Knop & Tina Vilsbøll. (2020) One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine 9:10, pages 3213.
Crossref
Angelo Maria Patti, Dragana Nikolic, Antonio Magan-Fernandez, Rosaria Vincenza Giglio, Giuseppa Castellino, Roberta Chianetta, Roberto Citarrella, Egle Corrado, Francesca Provenzano, Vincenzo Provenzano, Giuseppe Montalto, Ali A. Rizvi & Manfredi Rizzo. (2019) Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. Diabetes Research and Clinical Practice 149, pages 163-169.
Crossref
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S. McAdams, Ali A. Rizvi & Francesco Cosentino. (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:9, pages 2814-2821.
Crossref
Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E. O’Reilly, Margaret B. Lucitt, Catherine G. Godson, Fiona C. McGillicuddy & Orina Belton. (2017) Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovascular Diabetology 16:1.
Crossref
Manfredi Rizzo, Ali A. Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano, Stefano Genovese & Antonio Ceriello. (2016) Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology 15:1.
Crossref
Junzi Wu, Gareth R. Williams, Christopher Branford-White, Heyu Li, Yan Li & Li-Min Zhu. (2016) Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation. European Journal of Pharmaceutical Sciences 92, pages 28-38.
Crossref
Angelo Maria Patti, Niki Katsiki, Dragana Nikolic, Khalid Al-Rasadi & Manfredi Rizzo. (2014) Nutraceuticals in Lipid-Lowering Treatment. Angiology 66:5, pages 416-421.
Crossref
Manfredi Rizzo, Rosaria Vincenza Giglio, Dragana Nikolic, Angelo Maria Patti, Claudia Campanella, Massimo Cocchi, Niki Katsiki & Giuseppe Montalto. (2013) Effects of Chitosan on Plasma Lipids and Lipoproteins. Angiology 65:6, pages 538-542.
Crossref
Manfredi Rizzo, Dimitri P. Mikhailidis & Khalid Al-Rasadi. (2014) The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. Cardiovascular Drugs and Therapy 28:3, pages 205-207.
Crossref
Bob Ryder, John McKnightAndrew Blann, Ketan Dhatariya, Rob Gregory, Tony Robinson, Susannah Rowles, Patrick Sharp, Peter H Winocour & Chris Walton. (2013) ABCD position statement on GLP‐1 based therapies and pancreatic damage. Practical Diabetes 30:9, pages 388-391.
Crossref
R. E. J. Ryder. (2013) The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine 30:10, pages 1148-1155.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.